The role of the TAPSE/sPAP ratio as a predictor of mortality in Pulmonary Arterial Hypertension: Its value for patient risk stratification
A TAPSE/sPAP ratio <0.18 mm/mmHg predicts mortality in PAH. The combination of the TAPSE/sPAP ratio with the ESC/ERS risk score improved risk stratification, and reclassification emphasizing the potential of ESC/ERS+TAPSE/sPAP as a valuable tool for risk assessment and clinical decision-making in PAH patients. Integration of TAPSE/sPAP ratio with other scores (COMPERA and (REVEAL Lite 2) also improved the risk stratification and reclassification of these risk scores.
Authors
- Dulce Iliana Navarro‐Vergara (ORCID: https://orcid.org/0000-0001-8209-671X)
- Marisol García‐Cesar (ORCID: https://orcid.org/0000-0003-1645-3744)
- Jorge Arturo Ortega-Hernandez (ORCID: https://orcid.org/0000-0002-6019-2644)
- Carlos Alfredo Narváez-Oríani
- Paul Palacios-Moguel (ORCID: https://orcid.org/0000-0001-9983-2859)
- Julio Sandoval (ORCID: https://orcid.org/0000-0001-6825-3600)
- Maria-Berenice Torres-Rojas (ORCID: https://orcid.org/0000-0002-7843-7179)
- Guillermo Cueto‐Robledo (ORCID: https://orcid.org/0000-0003-3217-1595)
- Héctor González‐Pacheco (ORCID: https://orcid.org/0000-0002-4370-9963)
- Cinthia Alejandra González-Nájera
Institutions
- Hospital General de México (MX)
- Centro Médico ABC (MX)
- Instituto Nacional de Cardiología (MX)
- Institute for Social Security and Services for State Workers (MX)
Publication Details
- Journal
- JHLT Open
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1016/j.jhlto.2024.100168
- Citations
- 4
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.68